Skip to nav Skip to content
Doug  Cress

Doug Cress, PhD

Research Integrity Officer

Program: Molecular Oncology

Research Program: Cancer Biology & Evolution Program

Google Scholar Profile


  • Overview

    Lung malignancies are the leading cancer killer.  Research in the Cress laboratory seeks 1) to understand genetic and metabolic alterations that drive lung cancer, and 2) to develop novel therapeutics and therapeutic biomarkers based on this understanding.


    • Molecular Oncology
    • Thoracic Oncology
    • Lung Cancer Center of Excellence
    • Cancer Biology & Evolution Program

    Education & Training


    • Michigan State University, East Lansing, Michigan, PhD - Biochemistry


    • Duke University Medical Center, Durham, North Carolina - Molecular Genetics
  • Research Interest

    Research in the Cress laboratory addresses translational genetics of lung cancer; including genetic and metabolic alterations that drive lung cancer, the response of lung cancer to therapy and the development of biomarkers to guide therapeutic choices in lung cancer.  Current projects focus specifically on the molecular biology of EGFR and STK11 mutations with an interest in the role that altered metabolism plays in tumor progression and immune evasion.  As the co-Director of the Puerto Rico Biobank, Dr. Cress also has an emerging interest in the role that race, ethnicity, ancestry and genetics play in the molecular biology of lung cancer.

  • Publications

    • Lockhart JH, Ackerman HD, Lee K, Abdalah M, Davis AJ, Hackel N, Boyle TA, Saller J, Keske A, Hänggi K, Ruffell B, Stringfield O, Cress WD, Tan AC, Flores ER. Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI). NPJ Precis Oncol. 2023 Jul.7(1):68. Pubmedid: 37464050. Pmcid: PMC10354042.
    • Alhaddad H, Ospina OE, Khaled ML, Ren Y, Forsyth P, Pina Y, Macaulay R, Law V, Tsai KY, Cress WD, Fridley B, Smalley I. Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: 38187574. Pmcid: PMC10769278.
    • Trinh T, Adams WA, Calescibetta A, Tu N, Dalton R, So T, Wei M, Ward G, Kostenko E, Christiansen S, Cen L, McLemore A, Reed K, Whiting J, Gilvary D, Blanco NL, Segura CM, Nguyen J, Kandell W, Chen X, Cheng P, Wright GM, Cress WD, Liu J, Wright KL, Wei S, Eksioglu EA. CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience. 2023 Apr.26(4):106443. Pubmedid: 37070068. Pmcid: PMC10105289.
    • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2021 Jun.12(13):1325. Pubmedid: 34194632. Pmcid: PMC8238243.
    • Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS One. 2021 Jun.16(6):e0252927. Pubmedid: 34138895. Pmcid: PMC8211232.
    • Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. FEBS Open Bio. 2019 Oct.9(10):1689-1704. Pubmedid: 31314158. Pmcid: PMC6768113.
    • Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA. MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. Cancer Res. 2019 Nov.79(22):5812-5825. Pubmedid: 31362929. Pmcid: PMC6881545.
    • Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 2019 Jan.10(8):810-824. Pubmedid: 30783512. Pmcid: PMC6368226.
    • Pérez-Morales J, Mejías-Morales D, Rivera-Rivera S, González-Flores J, González-Loperena M, Cordero-Báez FY, Pedreira-García WM, Chardón-Colón C, Cabán-Rivera J, Cress WD, Gordian ER, Muñoz-Antonia T, Cabrera-Ríos M, Isidro A, Coppola D, Rosa M, Boyle TA, Izumi V, Koomen JM, Santiago-Cardona PG. Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. PLoS One. 2018 Nov.13(11):e0207483. Pubmedid: 30452490. Pmcid: PMC6242691.
    • Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, Berglund AE. Evaluating somatic tumor mutation detection without matched normal samples. Hum Genomics. 2017 Sep.11(1):22. Pubmedid: 28870239. Pmcid: PMC5584341.
    • Cress WD, Yu P, Wu J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. Int J Biochem Cell B. 2017 Oct.91(Pt B):98-101. Pubmedid: 28504190. Pmcid: PMC5641230.
    • Cress WD. A stitch in time and CDK9. Cell Cycle. 2017 May.16(9):823-824. Pubmedid: 28301263. Pmcid: PMC5444345.
    • Engel BE, Cress WD, Santiago-Cardona PG. THE RETINOBLASTOMA PROTEIN: A MASTER TUMOR SUPPRESSOR ACTS AS A LINK BETWEEN CELL CYCLE AND CELL ADHESION. Cell Health Cytoskelet. 2017 Jan.7:1-10. Pubmedid: 28090172. Pmcid: PMC5228373.
    • Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiaporri AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, Yabar-Berrocal A, Motta-Guerrero R, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD. Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients. J Thorac Oncol. 2017 Dec.12(12):1851-1856. Pubmedid: 28911955. Pmcid: PMC5701827.
    • Schabath MB, Cress D, Munoz-Antonia T. Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control. 2016 Oct.23(4):338-346. Pubmedid: 27842323. Pmcid: PMC5340153.
    • Chen Z, Li JL, Lin S, Cao C, Gimbrone NT, Yang R, Fu DA, Carper MB, Haura EB, Schabath MB, Lu J, Amelio AL, Cress WD, Kaye FJ, Wu L. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest. 2016 Jun.126(6):2267-2279. Pubmedid: 27140397. Pmcid: PMC4887185.
    • Chen L, Engel BE, Welsh EA, Yoder SJ, Brantley SG, Chen DT, Beg AA, Cao C, Kaye FJ, Haura EB, Schabath MB, Cress WD. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. J Thorac Oncol. 2016 Jun.11(6):838-849. Pubmedid: 26917230. Pmcid: PMC4877210.
    • Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016 Jun.35(24):3209-3216. Pubmedid: 26477306. Pmcid: PMC4837098.
    • Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther. 2016 Jul.15(7):1669-1681. Pubmedid: 27196765. Pmcid: PMC4936941.
    • Chen DT, Huang PY, Lin HY, Haura EB, Antonia SJ, Cress WD, Gray JE. Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget. 2016 Dec.7(49):80373-80381. Pubmedid: 27661007. Pmcid: PMC5348326.
    • Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016 Dec.7(50):82254-82265. Pubmedid: 27756884. Pmcid: PMC5347689.
    • Challa S, Guo J, Ding X, Xu CX, Li Y, Kim D, Smith MA, Cress WD, Coppola D, Haura EB, Cheng JQ. IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR. Cancer Res. 2016 Aug.76(15):4418-4429. Pubmedid: 27287717. Pmcid: PMC4970891.
    • Baldelli E, Haura EB, Crinò L, Cress WD, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M. Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. Proteom Clin Appl. 2015 Oct.9(9-10):928-937. Pubmedid: 25676683. Pmcid: PMC4547918.
    • Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF, Pierobon M. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget. 2015 Oct.6(32):32368-32379. Pubmedid: 26468985. Pmcid: PMC4741699.
    • Sosa-García B, Vázquez-Rivera V, González-Flores JN, Engel BE, Cress WD, Santiago-Cardona PG. The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts. PLoS One. 2015 Nov.10(11):e0142406. Pubmedid: 26555075. Pmcid: PMC4640669.
    • Cao C, Gao R, Zhang M, Amelio AL, Fallahi M, Chen Z, Gu Y, Hu C, Welsh EA, Engel BE, Haura EB, Cress WD, Wu L, Zajac-Kaye M, Kaye FJ. Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer. J Natl Cancer Inst. 2015 Jan.107(1):358. Pubmedid: 25465874. Pmcid: PMC4271078.
    • Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, Cai J, Cress WD, Wu J. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Brit J Cancer. 2015 Dec.113(12):1735-1743. Pubmedid: 26554648. Pmcid: PMC4701993.
    • Kurtyka CA, Chen L, Cress WD. E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One. 2014 May.9(5):e96357. Pubmedid: 24831239. Pmcid: PMC4022639.
    • Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB, Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014 Mar.111(11):4203-4208. Pubmedid: 24586048. Pmcid: PMC3964044.
    • Chen L, Muñoz-Antonia T, Cress WD. Trim28 contributes to EMT via regulation of E-cadherin and N-cadherin in lung cancer cell lines. PLoS One. 2014 Jul.9(7):e101040. Pubmedid: 24983967. Pmcid: PMC4077753.
    • Cress WD, Chiappori A, Santiago P, Muñoz-Antonia T. Lung cancer mutations and use of targeted agents in Hispanics. Rev Recent Clin Trials. 2014 Dec.9(4):225-232. Pubmedid: 25626064. Pmcid: PMC4441412.
    • Engel BE, Welsh E, Emmons MF, Santiago-Cardona PG, Cress WD. Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors. Cell Death Dis. 2013 Nov.4:e938. Pubmedid: 24287699. Pmcid: PMC3847337.
    • Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 2012 Nov.287(48):40106-40118. Pubmedid: 23060449. Pmcid: PMC3504725.
    • Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. PLoS One. 2012 Mar.6(10):e24923. Pubmedid: 22046235. Pmcid: PMC3203112.
    • Cress WD. E2F1: A new role in the DNA damage response. Cell Cycle. 2011 Jun.10(11):1718. Pubmedid: 21543892. Pmcid: PMC3685611.
    • Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011 Dec.103(24):1859-1870. Pubmedid: 22157961. Pmcid: PMC3243673.
    • Sosa-García B, Gunduz V, Vázquez-Rivera V, Cress WD, Wright G, Bian H, Hinds PW, Santiago-Cardona PG. A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation. PLoS One. 2010 Nov.5(11):e13954. Pubmedid: 21085651. Pmcid: PMC2978706.
    • Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD. CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem. 2010 Mar.285(13):9813-9822. Pubmedid: 20106982. Pmcid: PMC2843230.
    • Freeman SN, Cress WD. RhoBTB2 (DBC2) comes of age as a multifunctional tumor suppressor. Cancer Biol Ther. 2010 Dec.10(11):1123-1125. Pubmedid: 20980811.
    • Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, Altiok S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010 Dec.5(12):e14335. Pubmedid: 21179472. Pmcid: PMC3001870.
    • Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, Barrett A, Aslanidi G, Cress WD, Law B. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism. J Biol Chem. 2009 Oct.284(43):29945-29955. Pubmedid: 19710018. Pmcid: PMC2785623.
    • He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem. 2008 Nov.283(45):31012-31020. Pubmedid: 18776222. Pmcid: PMC2576560.
    • Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H. Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res. 2008 Jul.6(7):1099-1105. Pubmedid: 18644974. Pmcid: PMC2775817.
    • Freeman SN, Ma Y, Cress WD. RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis. J Biol Chem. 2008 Jan.283(4):2353-2362. Pubmedid: 18039672. Pmcid: PMC2268526.
    • Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W, Cress WD. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res. 2008 Aug.68(15):6292-6299. Pubmedid: 18676853. Pmcid: PMC3615411.
    • Wang C, Rauscher FJ 3rd, Cress W, Chen J. Regulation of E2F1 function by the nuclear co-repressor KAP-1. J Biol Chem. 2007 Oct.282(41):29902-9. Pubmedid: 17704056.
    • Ma Y, Cress W. Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity. Oncogene. 2007 May.26(24):3532-3540. Pubmedid: 17173074. Pmcid: PMC2128050.
    • Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD, Chen J. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006 Sep.8(9):1025-1031. Pubmedid: 16892051.
    • Rodriguez JM, Glozak MA, Ma Y, Cress WD. Bok, Bcl-2-related Ovarian Killer, Is Cell Cycle-regulated and Sensitizes to Stress-induced Apoptosis. J Biol Chem. 2006 Aug.281(32):22729-22735. Pubmedid: 16772296. Pmcid: PMC2134790.
    • Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005 Sep.25(17):7432-7440. Pubmedid: 16107692. Pmcid: PMC1190305.
    • Freeman S, Bepler G, Haura E, Sutphen R, Cress W. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst. 2005 Jul.97(14):1088-1089. Pubmedid: 16030308.
    • Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Cress W, Kim Y, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005 Feb.47(2):183-192. Pubmedid: 15639717.
    • Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, Chen J. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem. 2005 Apr.280(13):12339-12343. Pubmedid: 15713665.
    • Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer. 2004 Sep.6(2):113-122. Pubmedid: 15476597.
    • Wang J, Gamsby J, Highfill S, Mora L, Bloom G, Yeatman T, Pan T, Ramne A, Chodosh L, Cress W, Chen J, Kerr W. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene. 2004 May.23(23):4089-4097. Pubmedid: 15064745.
    • Hauser P, Ma L, Agrawal D, Haura E, Cress WD, Pledger WJ. Efficient down-regulation of cyclin A-associated activity and expression in suspended primary keratinocytes requires p21(Cip1). Mol Cancer Res. 2004 Feb.2(2):96-104. Pubmedid: 14985466.
    • Savell J, Ma Y, Morrow KS, Jove R, Olashaw N, Moseley PL, Cress WD, Wharton W. AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1. Mol Cancer Ther. 2004 Feb.3(2):205-213. Pubmedid: 14985461.
    • Ma Y, Freeman SN, Cress WD. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biol Ther. 2004 Dec.3(12):1262-1269. Pubmedid: 15611646.
    • Ma Y, Yuan J, Huang M, Jove R, Cress WD. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem. 2003 May.278(19):16770-16776. Pubmedid: 12611887.
    • Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther. 2003 Jan.2(1):73-81. Pubmedid: 12533675.
    • Wen YD, Cress WD, Roy AL, Seto E. Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J Biol Chem. 2003 Jan.278(3):1841-1847. Pubmedid: 12393887.
    • Ma Y, Croxton R, Moorer R, Cress W. Identification of novel E2F1-regulated genes by microarray. Arch Biochem Biophys. 2002 Mar.399(2):212-224. Pubmedid: 11888208.
    • Croxton R, Ma Y, Cress W. Differences in DNA binding properties between E2F1 and E2F4 specify repression of the Mcl-1 promoter. Oncogene. 2002 Feb.21(10):1563-1570. Pubmedid: 11896585.
    • Croxton R, Ma Y, Song L, Haura E, Cress W. Direct repression of the Mcl-1 promoter by E2F1. Oncogene. 2002 Feb.21(9):1359-1369. Pubmedid: 11857079.
    • He Y, Cress W. E2F-3B is a physiological target of cyclin A. J Biol Chem. 2002.277(26):23493-23499. Pubmedid: 11980909.
    • Cuenca A, Cress W, Good R, Marikar Y, Engelman R. Calorie restriction influences cell cycle protein expression and DNA synthesis during liver regeneration. Exp Biol Med (Maywood). 2001 Dec.226(11):1061-1067. Pubmedid: 11743143.
    • Hu X, Cress, Jr. W, Zhong Q, Zuckerman K. Transforming growth factor beta inhibits the phosphorylation of pRB at multiple serine/threonine sites and differentially regulates the formation of pRB family-E2F complexes in human myeloid leukemia cells. Biochem Bioph Res Co. 2000 Oct.276(3):930-939. Pubmedid: 11027571.
    • Wharton W, Savell J, Cress WD, Seto E, Pledger WJ. Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem. 2000 Oct.275(43):33981-33987. Pubmedid: 10945992.
    • Zhang X, Wharton W, Donovan M, Coppola D, Croxton R, Cress WD, Pledger WJ. Density-dependent growth inhibition of fibroblasts ectopically expressing p27(kip1). Mol Biol Cell. 2000 Jun.11(6):2117-2130. Pubmedid: 10848633.
    • Cress, Jr. W, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000 Jul.184(1):1-16. Pubmedid: 10825229.
    • He Y, Armanious M, Thomas MJ, Cress, Jr. W. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene. 2000 Jul.19(30):3422-3433. Pubmedid: 10918599.
    • Flores A, Kassatly R, Cress, Jr. W. E2F-3 accumulation is regulated by polypeptide stability. Oncogene. 1998 Mar.16(10):1289-1298. Pubmedid: 9546430.
    • Dong F, Cress WD, Agrawal D, Pledger WJ. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. J Biol Chem. 1998 Mar.273(11):6190-6195. Pubmedid: 9497341.
    • Tao Y, Kassatly R, Cress, Jr. W, Horowitz J. Subunit composition determines E2F DNA-binding site specificity. Mol Cell Biol. 1997.17(12):6994-7007. Pubmedid: 9372931.
    • Cress, Jr. W, Nevins J. A role for bent DNA structure in E2F-mediated transcription activation. Mol Cell Biol. 1996.16:2119-2127. Pubmedid: 8628278.
    • Cress, Jr. W, Nevins J. Interacting domains of E2F1, DP1 and the adenovirus E4 protein. J Virol. 1994.68:4212-4219.
    • Cress, Jr. W, Johnson J, Nevins J. Genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107 and adenovirus E4. Mol Cell Biol. 1993.13:6314-6325.
    • Johnson D, Schwarz J, Cress, Jr. W, Nevins J. Expression of transcription factor E2F1 can induce quiescent cells to enter S phase. Nature. 1993.365:349-352.
    • Cress, Jr. W, Nevins J. Use of the E2F transcription factor by DNA tumor virus regulatory proteins. In: P. J. Farnham, ed. Current topics in microbiology and immunology. 208 ed. Germany. Springer Verlag Berlin Heidelberg; 1996.
  • Grants

    • Title: Understanding the mechanisms by which STK11 loss in lung cancer leads to immune invasion
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI: Cress, D.
    • Title: Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas
      Sponsor: Nat Institutes of Health
      PI (MPI): Cress, D.
    • Title: Identifying Metabolic Vulnerabilities in Lung Cancer
      Sponsor: Nat Institutes of Health
      PI (Contact): Flores, E., PI (MPI): Haura, E., Project PI: DeNicola, G., Project PI: Rodriguez, P., Project PI: Cleveland, J., Core PI/Director: Cress, D., Core PI/Director: Koomen, J.
    • Title: Integrated Program in Cancer and Data Science
      Sponsor: Nat Institutes of Health
      PI (Contact): Cress, D., PI (MPI): Flores, E., PI (MPI): Fridley, B.

Find a Researcher Search